Home > Dangerous Drugs > Canadian Government Warns Of Risk Of Retinal Damage From Elmiron

Canadian Government Warns Of Risk Of Retinal Damage From Elmiron

Canadian Government Warns Of Risk Of Retinal Damage From Elmiron

The Canadian government has issued a safety alert about the risk of a form of retinal damage known as pigmentary maculopathy which is associated with Elmiron.

The alert states that pigmentary maculopathy cases have been reported regarding Elmiron and long-term use, and that the interstitial cystitis drug is now contraindicated in patients with a macular pathology history.

The alert advises healthcare professionals to assess the benefits and risks of Elmiron with patients, obtain all patients’ detailed ophthalmologic history before starting them on Elmiron, perform regular and baseline retinal exams to detect macular pathology early and advise patients to report vision changes such as wavy or blurry vision in or near the center of one’s vision field, slow adjustment to reduced or low light or problems reading.

The alert states that most retinal changes occur in patients who have taken Elmiron for three years or longer, but that some cases have been seen in a shorter time period. The alert states that the retinal changes can lead to permanent vision loss.

Study Discovers Dose/Response Association Between Eye Damage And Elmiron

A recent study found that “those in the highest PPS exposure category were more likely to have difficulties reading small print and to report a prior diagnosis of macular disease,” suggesting that the risk for eye damage increases as one is exposed to more and more Elmiron.

The study had 912 respondents with interstitial cystitis complete a 27-item online survey.

Lawsuit Alleges Elmiron Use Caused Illinois Man To Suffer From Vision Damage

A lawsuit filed on December 1 in federal court in Illinois alleges that the use of Elmiron from 1997 through 2003 caused an Illinois man to develop difficulty reading, difficulty adapting to dim lighting, and cloudy, distorted and blurred vision.

The lawsuit claims that the defendants, including Janssen Pharmaceuticals, Johnson & Johnson and Ortho-McNeil Pharmaceuticals, knew or should have known that Elmiron posed a risk of vision damage yet failed to warn the public about the risk.

The lawsuit notes that the new, unique eye disease which Elmiron allegedly causes was noted in findings published in 2018 by the Emory Eye Center. Researchers there found six patients with a new, novel form of eye damage, poured through their patient histories and discovered that all six patients had taken Elmiron.

The lawsuit seeks to recover damages based on multiple counts, including:


January 11, 2021

Lawsuit Claims Long-Term Elmiron Use Led To Cloudy, Blurred Vision

A lawsuit filed in federal court in New York on Thursday alleges that use o...

October 17, 2020

Lawsuit alleges Elmiron makers knew it could cause vision loss

A lawsuit filed in federal court in Florida on October 9 claims that Elmiro...

October 6, 2020

Marksans Recalls More Metformin Due To Probable Carcinogen

Marksans Pharma Limited has expanded its voluntary nationwide recall of 500...